AZ to collaborate with Syndax on immune-oncology trials of durvalumab + SNDX-6352 in solid tumors

AstraZeneca (AZ) and Syndax Pharmaceuticals start a new clinical collaboration to evaluate the safety and efficacy of durvalumab (a human monoclonal antibody [mAb] directed against programmed death-ligand 1), in combination with SNDX-6352 (mAb inhibitor of colony-stimulating factor 1 receptor). Under the terms of the agreement, Syndax and AZ will collaborate on a non-exclusive basis to evaluate the combination of the 2 drugs in multiple solid tumor types. Syndax expects to initiate a phase Ib study in the first half of 2018 to establish the safety and recommended dose regimen of SNDX-6352 in combination with durvalumab. Data from this study will enable both companies to sponsor, design, and initiate subsequent phase II studies aimed at exploring the safety and efficacy of the combination across a number of defined tumor types.

Click here to go to the full article

Are you ready to explore new ideas?

Learn the many ways TRM Oncology can support you and your valued stakeholders.

All Fields Required